

Split-Fill List* - April 2018



Brand Name	Generic Name	Manufacturer(s)	Recommendation	Duration	Quantity	Days' Supply
Afinitor	Everolimus	Novartis	Recommended	3 months	14	14
Bosulif	Bosutinib	Pfizer	Recommended	3 months	15	15
Cabometyx	Cabozantinib	Exelixis	Recommended	3 months	15	15
Cometriq	Cabozantinib	Exelixis	Recommended	3 months	14 (80 mg) or 42 (20 mg)	14
Erivedge	Vismodegib	Genentech	Recommended	3 months	14	14
Esbriet	Pirfenidone	Genentech	Recommended	3 months	Varies	14
Exjade	Deferasirox	Novartis	Recommended	3 months	Varies	15
Gleevec	Imatinib Mesylate	Novartis; Generic Manufacturer(s)	Recommended	3 months	Varies	15
Imbruvica	Ibrutinib	Pharmacyclics; Janssen	Recommended	3 months	45 or 60 (diagnosis dependent)	15
Inlyta	Axitinib	Pfizer	Recommended	3 months	30	15
Jadenu	Deferasirox	Novartis	Recommended	3 months	Varies	15
Jakafi	Ruxolitinib	Incyte	Recommended	3 months	30	15
Nerlynx	Neratinib	Puma	Recommended	3 months	90	15
Nexavar	Sorafenib	Bayer	Recommended	3 months	60	15
Odomzo	Sonidegib	Novartis	Recommended	3 months	15	15
Sprycel	Dasatinib	Bristol-Myers Squibb	Recommended	3 months	15 (Weight-based dosing - Varies)	15
Sutent	Sunitinib Malate	Pfizer	Recommended	3 months	14	14
Tafinlar	Dabrafenib	Novartis	Recommended	3 months	60	15
Tagrisso	Osimertinib	AstraZeneca	Recommended	3 months	15	15
Tarceva	Erlotinib	Genentech	Recommended	3 months	15	15
Tasigna	Nilotinib	Novartis	Recommended	3 months	28 (2 blisters)	14
Verzenio	Abemaciclib	Lilly	Recommended	3 months	28 (2 blisters)	14
Votrient	Pazopanib	Novartis	Recommended	3 months	60	15
Xalkori	Crizotinib	Pfizer	Recommended	3 months	30	15
Xtandi	Enzalutamide	Astellas	Recommended	3 months	60	15
ZeJula	Niraparib	Tesaro	Recommended	3 months	45	15
Zolanza	Vorinostat	Merck	Recommended	3 months	60	15
Zykadia	Ceritinib	Novartis	Recommended	3 months	70	14
Austedo	Deutetrabenazine	Teva	Not Recommended	N/A	N/A	N/A
Calquence	Acalabrutinib	AstraZeneca	Not Recommended	N/A	N/A	N/A
Cotellic	Cobimetinib	Genentech	Not Recommended	N/A	N/A	N/A
Daklinza	Daclatasvir	Bristol-Myers Squibb; Gilead	Not Recommended	N/A	N/A	N/A
Epclusa	Velpatasvir + sofosbuvir	Gilead	Not Recommended	N/A	N/A	N/A
Harvoni	Sofosbuvir + Ledipasvir	Gilead	Not Recommended	N/A	N/A	N/A
Hetlioz	Tasimeleone	Vanda	Not Recommended	N/A	N/A	N/A
Hycamtin	Topotecan hydrochloride	GlaxoSmithKline	Not Recommended	N/A	N/A	N/A
Ibrance	Palbociclib	Pfizer	Not Recommended	N/A	N/A	N/A
Imfinzi	Durvalumab	AstraZeneca	Not Recommended	N/A	N/A	N/A
Iressa	Gefitinib	AstraZeneca	Not Recommended	N/A	N/A	N/A
Kalydeco	Ivacaftor	Vertex	Not Recommended	N/A	N/A	N/A
Kevzara	Sarilumab	Sanofi; Genzyme	Not Recommended	N/A	N/A	N/A
Kisqali	Ribociclib	Novartis	Not Recommended	N/A	N/A	N/A
Mavyret	Glecaprevir + pibrentasvir	Abbvie	Not Recommended	N/A	N/A	N/A
Nityr	Nitisinone	Cycle	Not Recommended	N/A	N/A	N/A
Nplate	Romiplostim	Amgen	Not Recommended	N/A	N/A	N/A
Olysio	Simeprevir	Janssen	Not Recommended	N/A	N/A	N/A
Orkambi	Lumacaftor/ivacaftor	Vertex	Not Recommended	N/A	N/A	N/A
Otezla	Apremilast	Celgene	Not Recommended	N/A	N/A	N/A
Pomalyst	Pomalidomide	Celgene	Not Recommended	N/A	N/A	N/A
Retrovir	Zidovudine	GlaxoSmithKline; TBU	Not Recommended	N/A	N/A	N/A

Split-Fill List* - April 2018



Brand Name	Generic Name	Manufacturer(s)	Recommendation	Duration	Quantity	Days' Supply
Revlimid	Lenalidomide	Celgene	Not Recommended	N/A	N/A	N/A
RibaPak, Ribasphere Caps, Ribasphere Tabs, Ribavirin Tabs, Moderiba, Rebetol, Copegus	Ribavirin	Kadmon; TBU; AbbVie; Schering; Genentech	Not Recommended	N/A	N/A	N/A
Rydapt	Midostaurin	Novartis	Not Recommended	N/A	N/A	N/A
Selzentry	Maraviroc	Pfizer	Not Recommended	N/A	N/A	N/A
Sovaldi	Sofosbuvir	Gilead	Not Recommended	N/A	N/A	N/A
Stivarga	Regorafenib	Bayer	Not Recommended	N/A	N/A	N/A
Symdeko	Tezacaftor/ivacaftor	Vertex	Not Recommended	N/A	N/A	N/A
Targretin	Bexarotene	Valeant	Not Recommended	N/A	N/A	N/A
Tecfidera	Dimethyl fumarate	Biogen	Not Recommended	N/A	N/A	N/A
Temodar	Temozolomide	Merck; Generic Manufacturers	Not Recommended	N/A	N/A	N/A
Venclexta	Venetoclax	Abbvie; Genentech	Not Recommended	N/A	N/A	N/A
Viekira XR	Ombitasvir + paritaprevir + ritonavir + dasabuvir	Abbvie	Not Recommended	N/A	N/A	N/A
Vosevi	Voxilaprevir + sofosbuvir + velpatasvir	Gilead	Not Recommended	N/A	N/A	N/A
Xeloda	Capecitabine	Genentech	Not Recommended	N/A	N/A	N/A
Xermelo	Telotristat ethyl	Lexicon	Not Recommended	N/A	N/A	N/A
Zelboraf	Vemurafenib	Genentech	Not Recommended	N/A	N/A	N/A
Zepatier	Grazoprevir + elbasvir	Merck	Not Recommended	N/A	N/A	N/A
Zytiga	Abiraterone Acetate	Janssen	Not Recommended	N/A	N/A	N/A

Recommended - Products with high risk of discontinuation, high rate dose modifications, and no clinical/kinetic concerns per clinical trials;

Not Recommended - Products with limited to no risk of discontinuation, dose modifications or that may have a specific clinical/kinetic concerns per clinical trials, but can physically be split/filled.

*The information contained herein is for informational purposes only and is subject to change without notice. Diplomat Pharmacy Inc. takes no responsibility for the accuracy or validity of the information contained herein, nor the claims or statements of any manufacturer.

Copyright © 2018 by Diplomat Pharmacy Inc. All rights reserved. Diplomat is a trademark of Diplomat Pharmacy Inc. Last Update: 4/26/18